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Abstract
Background: HIV and tuberculosis (TB) are commonly associated. Identifying latent and asymptomatic tuberculosis
infection in HIV-positive patients is important in preventing death and morbidity associated with active TB.
Methods: Cross-sectional study of one time use of an interferon-gamma release assay (T-SPOT.TB - immunospot) to
detect tuberculosis infection in patients in a UK inner city HIV clinic with a large sub-Saharan population.
Results: 542 patient samples from 520 patients who disclosed their symptoms of TB were tested. Median follow-up
was 35 months (range 27-69). More than half (55%) originated from countries with medium or high tuberculosis
burden and 57% were women. Antiretroviral therapy was used by 67%; median CD4 count at test was 458 cells/μl. A
negative test was found in 452 samples and an indeterminate results in 40 (7.4%) but neither were associated with a
low CD4 count. A positive test was found in 10% (50/502) individuals. All patients with positive tests were referred to
the TB specialist, 47 (94%) had a chest radiograph and 46 (92%) attended the TB clinic. Two had culture-positive TB and
a third individual with features of active TB was treated. 40 started and 38 completed preventive treatment. One patient
who completed preventive treatment with isoniazid monotherapy subsequently developed isoniazid-resistant
pulmonary tuberculosis. No patient with a negative test has developed TB.
Conclusions: We found an overall prevalence of latent TB infection of 10% through screening for TB in those with HIV
infection and without symptoms, and a further 1% with active disease, a yield greater than typically found in contact
tracing. Acceptability of preventive treatment was high with 85% of those with latent TB infection eventually
completing their TB chemotherapy regimens. IGRA-based TB screening among HIV-infected individuals was feasible in
the clinical setting and assisted with appropriate management (including preventive treatment and therapy for active
disease). Follow-up of TB incidence in this group is needed to assess the long-term effects of preventive treatment.
Background
In 1998, the World Health Organization recommended
detection of latent tuberculosis infection (LTBI) in HIV
infected individuals in order to institute preventive treat-
ment [1]. Currently, in resource constrained settings, iso-
niazid preventive therapy is recommended for those
likely to have LTBI, but research is required to evaluate
the role of tests to identify tuberculosis (TB) and LTBI
[2]. Interferon-gamma release assays (IGRAs) have a
higher sensitivity in patients with lower CD4 counts and
greater specificity in those from areas with a low incidence
of TB than the tuberculin skin test; although in active dis-
ease the sensitivity is still about 80% [3]. The T-SPOTW.TB
(immunospot) assay may have a higher sensitivity with
fewer indeterminate results in immunosuppressed patients
than the QuantiFERON-TB Gold [3]. This may be because
the immunospot uses a fixed number of peripheral blood
mononuclear cells and should therefore be less affected by
the CD4 lymphocyte count.
In low TB burden countries, the role of IGRAs in screen-
ing HIV infected individuals has yet to be established. The
United States Center for Disease Control guidelines advo-
cate testing for LTBI at HIV diagnosis regardless of TB risk
category [4] whereas UK national guidelines suggest an
approach based on region of origin, CD4 count and length
of time on antiretrovirals [5]. However, there are limited
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data on the utility of IGRAs as a screening tool in a low in-
cidence clinical setting and on the management of positive
results [6-8].
Homerton University Hospital is situated in Hackney,
London with an HIV prevalence five times the national
average (825 versus 164 per 100,000 population) [9], and
annual TB incidence four times the national average (58
versus 15 per 100,000 population) [10]. The area has
high numbers of migrants from sub-Saharan Africa. Over
a third of the HIV patient cohort is from high tubercu-
losis burden countries, as defined by WHO criteria [11].
Approximately two thirds were diagnosed with HIV at a
late stage of infection (CD4< 350 cells/μl). The aims of
this study were to evaluate the use of an IGRA in screen-
ing for latent or symptomless active TB in a cohort of
patients with HIV infection, and to determine the com-
pletion rate of preventive treatment in patients with
positive tests.
Methods
Study population, design, and entry criteria
All patients (~600) attending the HIV outpatient clinic
at Homerton University Hospital from April 2006 until
October 2009 were eligible for screening, except those
who were currently being investigated or treated for ac-
tive TB and patients who ever received treatment for
suspected or confirmed TB (n = 93). Recruitment was
carried out in two phases. In phase one (April 2006 to
April 2008) the immunospot assay was offered one day
per week as a pilot study funded by the Department of
Health, the results of which have been reported in an ab-
stract [12]. In phase two, the Primary Care Trust agreed
to expand screening to the remaining cohort as part of
standard clinical care. Informed consent was obtained
from patients who took part in the initial pilot study.
Patients were asked whether they had cough, fever, night
sweats or weight loss, as recommended by the WHO
screening program [13]. The number of HIV/TB co-
infected individuals treated at this hospital provided the
denominator to measure the effect of screening.
Immunospot assay
Venous blood samples were drawn and transported to
the hospital microbiology laboratory on the day of col-
lection. The T-SPOTW.TB assay (Oxford Immunotec,
Oxford, UK) is a commercially available enzyme-linked
immunospot assay which uses a fixed number of periph-
eral blood mononuclear cells. Blood samples were pro-
cessed using standard operating procedure OXIM.
SOP06-001. Positive and negative controls were included
to validate the result. A result was considered positive if
the number of spot-forming cells obtained from test
antigens was more than twice the number of the negative
control and had six or more spots than the negative
control. Wherever possible, patients with indeterminate
results had a second sample tested.
Clinical management of patients with positive result
Patients with positive results were referred to a TB spe-
cialist physician. All patients had a further symptom as-
sessment, chest radiograph, and sputum (three samples if
productive or at least one induced sputum with hyper-
tonic 3% saline) sent for smear microscopy and myco-
bacterial culture. Further investigations were carried out
in line with clinical findings. Referral to the TB specialist
was delayed for three months for individuals commen-
cing highly active antiretroviral therapy (HAART) to ob-
serve symptoms of TB that might emerge as a result of
immune reconstitution.
The decision to initiate preventive treatment was made
by the TB physician after discussion with the patient
regarding the risks and benefits. Patients on HAART
were offered six months of isoniazid as recommended in
national guidelines [14]. Those not on HAART had the
option of three months rifampicin and isoniazid [15].
Without HAART, rifampicin posed no risk of drug inter-
actions and patients could be involved in the choice of
treatment, a process which enhances adherence [16].
Where active tuberculosis was suspected, two months of
rifampicin, isoniazid and pyrazinamide were given, with
or without ethambutol depending on clinical suspicion
and likelihood of drug-resistance [17,18]. If active infec-
tion was proven or likely from the response to treatment
(i.e. weight gain, resolution of radiographic changes), the
standard six month anti-tuberculosis regimen was con-
tinued or modified according to drug sensitivities. If ac-
tive TB was ultimately excluded, the regimen of two
months rifampicin and pyrazinamide was considered suf-
ficient preventive treatment [15]. In severely immuno-
suppressed patients, TB prophylaxis was continued until
CD4> 200 cells/μl [19]. Those declining to attend the
TB clinic were offered follow-up and preventive treat-
ment in the HIV clinic.
Data handling and statistical analysis
Patient details including age, sex, ethnicity, country of
origin, CD4 count at test and receipt of antiretroviral
therapy were collected. The Shapiro-Wilk test was used
to test for normality of continuous variables. Differences
in proportions of categorical variables were tested using
χ2 test, and differences in median values of continuous
variables were tested using the Kruskal-Wallis test. Uni-
variate analysis was performed using logistic regression.
Odds ratio and 95% confidence interval (OR, 95% CI)
were used to measure the association between different
variables and immunospot result. All statistical calcula-
tions were performed using STATA (Stata Statistical
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Software: Release 11. College Station, TX: StataCorp LP.
2009).
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Over half (57%) of the cohort were women and 55% were
patients from medium or high prevalence TB countries
(30-300 and >300 cases per 100,000 population, respect-
ively, Table 1). 542 blood samples were collected from 520
patients (138 patients in the pilot study and 382 in the
expanded phase, including 22 patients who had repeat
samples tested after their first sample gave an indetermin-
ate result). The immunospot assay yielded 452 negative
results, 50 positive results, and 40 indeterminate results
(Figure 1).
Indeterminate and borderline results
After the first round of testing, 36 patients gave an indeter-
minate test. Twenty-two patients were retested, of whom
17 were negative, two positive, and four indeterminate for
a second time. Thus, out of 542 tests, 40 (7.4%) were inde-
terminate. The reasons for an indeterminate test were: 15
samples had a low cell number (too few circulating T-cells
to produce interferon-gamma); in 11 the positive control
failed; nine had a high background in the negative control
panel; three failed to separate cells after centrifugation;
and CO2 flow failure affected test performance in two
tests. Median CD4 count for the forty indeterminate test
results was 503 cells/μl (IQR 401-606), compared to 456
cells/μl (IQR 310-610) for the 502 determinate (positive or
negative) tests. Low CD4 count at test was not associated
with an indeterminate result (p= 0.198).
In the United States, the immunospot test has a border-
line category, in which those with 5-7 spots are placed [4].
Analysing our data by these criteria, five patients with a
negative response would have been classified as borderline
– none have since developed TB. A further 5, who were
classified as reactive, would have been assigned borderline
status, all of whom completed preventive treatment and
did not develop TB.
Analysis of positive and negative immunospot results
A comparison of demographic and clinical characteristics
of those with positive and negative results is shown in
Table 2. Excluding the 10 with a borderline result did
not change any of the significant differences between
negative and positive individuals.
Sex, age and the proportion of individuals receiving
HAART were similar between the two groups. Subgroup
analysis of patients on HAART showed that the mean dur-
ation of antiretroviral exposure between positive and nega-
tive tests was not significantly different (4.1 vs. 3.5 years,
P=0.352).
A higher proportion of patients of black African ethni-
city had a positive immunospot result compared to
others (13.0% vs. 4.7%); however ethnicity was not sig-
nificant predictor of test outcome in the regression
model. Being from a high TB prevalence country (OR,
5.01; 95% CI, 1.75–14.36; P=0.003) or medium TB preva-
lence country (OR, 3.73; 95% CI, 1.11-12.52; P=0.033)
were the only significant predictors of a positive immuno-
spot test.
Investigation for active TB
All fifty patients with positive immunospot tests were re-
ferred to the TB specialist. Forty seven (94%) patients
had chest radiographs, 11 of which were abnormal
(Table 3). Sputum samples were taken from 30 (60%)
patients and included all with an abnormal chest radio-
graph; the remainder were unable to produce a sample









Female (%) 296 (57)




CD4 cells/μl median (IQR) 458 (312-631)
Receiving HAART (%) 348 (67)
Ethnicity
White British 53 (10)
Black African 334 (64)
Asian 15 (3)
Black Caribbean 43 (8)
Other/mixed 75 (14)
TB prevalence in country of origin per 100,000 (%)
Low (<30) 141 (27)
Medium (30-300) 92 (18)
High (>300) 287 (55)
IQR = interquartile range.
HAART = highly active anti-retroviral therapy.
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despite the use of hypertonic saline to induce sputum.
Twenty-five patients gave induced sputum samples, four
had a productive cough, and one patient with abnormal
chest radiography underwent bronchoalveolar lavage.
Three women were diagnosed with subclinical active
TB. One individual without any symptoms and a normal
chest radiograph had a positive immunospot and sputum
culture grew Mycobacterium tuberculosis. Another had
previously denied any symptoms, but when questioned
more closely after the positive immunospot and abnor-
mal chest x-ray, then reported symptoms and was also
culture-positive. A third showed significant weight gain
after treatment for TB and did not take any treatment
for HIV during the time of the study. Thus, subclinical
tuberculosis was detected in 0.6% (3/502) of those who
tested and 6% (3/50) of those with a positive result. A
positive result was encountered in a patient with M.
xenopi infection who had no risk factors for exposure to
TB. During the same period of study, two patients with
symptoms and who were therefore not included in the
screening cohort proved to have TB and had a positive
immunospot test. During the study period, a total of 33
HIV-infected patients were under treatment for active
tuberculosis at the hospital, of which nearly 10% (3/33)
had been initially diagnosed through screening the
asymptomatic HIV-infected population.
Latent TB infection: prevalence and treatment
The prevalence of diagnosed latent TB infection was 9.2%
(46/502 i.e. excluding three with active TB and one prob-
ably false positive from M. Xenopi, out of those patients
with a determinate result.) (Figure 1). All except two were
offered preventive treatment and 40 (87%) commenced
treatment. Reasons for not starting preventive treatment
included non-attendance at appointments (3), patient re-
fusal due to low perceived risk of TB infection (2), and de-
ferral due to multiple co-morbidities (1). Thirty-five
patients chose to be managed in the TB clinic and five
chose the HIV clinic. To date, 38 (95%) have completed
treatment, one stopped 10 days before completing 6
months treatment with isoniazid and another stopped at 6
months although the CD4 count was 131 cells/μl.
Follow up of incident tuberculosis
The median duration of follow-up from immunospot test-




1 patient had history of M.
Xenopi, no risk factors for TB
46 patients LTBI 
diagnosed
3 patients sub-clinical 
active TB diagnosed
6 patients did not start preventive treatment
3 lost to follow-up
2 patient refusal
1 deferred (multiple co-morbidities)
40 patients started preventive treatment
6 months H (n=33)
3 months RH (n=5)
2 months RHZ (n=2)




48 positive tests436 negative tests
Figure 1 Flow diagram of patients tested with the immunospot test and subsequent diagnosis and treatment of LTBI. TB, tuberculosis;
LTBI, latent tuberculosis infection; Drug regimens are abbreviated to the letters for the drugs administered: H, isoniazid; R, rifampicin; Z,
pyrazinamide.
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a negative immunospot has developed TB. One patient who
had a positive test and was treated with six months isonia-
zid was subsequently diagnosed with isoniazid-resistant pul-
monary TB after two years (Table 3, Patient 10). The
patient successfully completed tuberculosis treatment with
rifampicin, pyrazinamide, ethambutol, moxifloxacin and
streptomycin.
Discussion
This paper has shown that screening for TB amongst
those living with HIV is feasible. Screening showed that
about 10% of our HIV clinic population were latently
infected with TB, and three cases of active sub-clinical
TB were detected. Screening among those with HIV is as
effective as contact tracing, a standard procedure in TB
control programs [14]. Since our study, the UK National
Institute for Clinical Excellence (NICE) has issued guide-
lines which recommend IGRA testing for people with
HIV (with CD4 200-500 cells/μl, and alongside a Man-
toux test if CD4< 200 cells/μl) and, if the test is positive,
performing a clinical assessment to exclude TB and con-
sider treating latent TB infection [20]. Our study sup-
ports these recommendations, although it is notable that
we did not observe the test result to be sensitive to CD4
count.
Various algorithms have been used to detect active TB in
those with HIV infection [21,22]. Symptom screening has
been advocated. However, people living with HIV in South
Africa and Zimbabwe also have high rates of active TB
even when they are asymptomatic [23,24]. In this study,
one patient did not admit to any symptoms until a positive
test provoked further direct inquiry. Chest radiography is
of limited usefulness and is complicated by atypical
presentations and even a normal appearance in 14-23% of
patients with culture-positive pulmonary disease and HIV
co-infection [25,26]. A study in Tanzania found that of
asymptomatic HIV-infected adults (CD4 >200, no TB
symptoms and a normal chest radiograph), 5% had active
TB diagnosed on positive sputum cultures [27]. Sputum
examination is used, especially in areas of high TB inci-
dence to detect active TB in those with HIV infection. A
recent meta-analysis found that intensified case finding
with microbiological investigation (sputum smear or
culture) in all patients, irrespective of symptoms, detected
an additional four TB cases per 100 HIV-infected indivi-
duals screened [28] and has been especially effective in
areas of high TB incidence [29]. This was our rationale for
collecting induced sputum even when history, examin-
ation, and chest radiograph were unremarkable. However,
only 60% of those without sputum were able to provide a
sample after nebulised hypertonic saline in this setting. In
an area of low incidence of TB, a combination of symp-
toms, previous exposure to TB, previous use of HAART,
weight <60 kg, CD4 count< 250/μl [30], sputum smear
and culture with or without an interferon-gamma release
assay were the best option. However, we should note that
two patients with active TB who denied any symptoms
were only investigated further because of a positive immu-
nospot test (Table 3), and therefore would have not been
identified by the suggested algorithms. A systematic review
of the interferon-gamma release assays in HIV/TB co-
infection has noted a sensitivity of 80% [3].
The rate at which those with a positive immunospot and
HIV might develop TB is unknown. The importance of
treating latent TB infection in those with HIV infection is
suggested by earlier studies with the tuberculin skin test
[31]. The interferon-gamma release assays were more
accurate than the tuberculin skin test in predicting both
progression to active disease and, in those with a negative
test, the absence of progression [32]. A recent systematic
review has suggested that these tests may be less useful in
low or middle-income countries [33]. However, using the
Table 2 Univariate analysis of factors associated with a
positive immunospot test*









15-24 14 1 1 0.867
25-34 117 12 1.44 (0.17-11.80)
35-44 197 25 1.78 (0.22-14.09)
45-54 92 10 1.52 (0.18-12.82)
55+ 32 2 0.87 (0.07-10.46)
CD4 count
≤350 302 38 1 0.368
200 – 349 101 7 0.55
<200 49 5 0.81
Female (%) 255 (57) 29 (58) 1.06 (0.59-1.93) 0.830
HAART (%) 304 (67) 33 (66) 0.94 (0.51-1.75) 0.858
Ethnicity
White British 49 1 1 0.078
Black African 282 42 7.30 (0.98-54.26)
Asian 14 1 3.50 (0.21-59.59)
Black Caribbean 39 3 3.77 (0.38-37.67)
Other/mixed 68 3 2.16 (0.22-21.41)
TB prevalence in
country of origin per
100,000
Low (<30) 131 4 1
Medium (30-300) 79 9 3.73 (1.11-12.52) 0.033
High (>300) 242 37 5.01 (1.75-14.36) 0.003
*Analysis includes individuals with borderline results as defined by the CDC,
United States [4].
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Clinical features Chest radiograph Sputum culture Other investigations Treatment Final diagnosis
1 Zimbabwe 413 Yes No symptoms Normal Positive
M. tuberculosis –
fully sensitive
2RHEZ, 4RH Pulmonary TB
2 Cameroon 350 No Posterior cervical
lymphadenopathy




3 Turkey 331 Yes Back pain and spinal
tenderness
Normal None received MRI spine normal 6H LTBI
4 Burundi 843 No Memory problems;
schizoaffective disorder
Recent weight loss


















6* Jamaica 539 No Paranoid schizophrenia Large emphysematous
bullae
Negative Inflammatory markers 6H LTBI
7* Nigeria 402 Yes No symptoms Blunting of left
costophrenic angle
None received Inflammatory markers 6H LTBI




Negative Inflammatory markers 6H LTBI





Negative Inflammatory markers 6H LTBI
10 Uganda 980 Yes No symptoms Peribronchial thickening






TB 2 years later
11 UK 345 No Epilepsy Left hilum appears
bulky
Negative CXR at 6 months
no change
3RH LTBI




Negative Normal echocardiogram 6H LTBI




























Table 3 Patients with positive immunospot test with symptoms suggestive of possible TB, abnormal chest radiograph or positive sputum culture (Continued)
14 Zambia 829 Yes General aches 2cm lung nodule Negative Vitamin D levels
low
6H LTBI


















splenomegaly, FNA – TB
2RHEZ, 4RH Pulmonary and
lymph node TB
*Borderline results as defined by the CDC, United States [4].
HAART, antiretroviral therapy; TB, tuberculosis; CXR, chest radiograph; LTBI, latent tuberculosis infection; FNA, fine needle aspirate; MRI, magnetic resonance imaging; CT, computerised tomography.
All patients had a chest radiograph and were offered induced sputum for mycobacterial culture in addition to inflammatory markers.


















less sensitive tuberculin skin test in a low TB incidence
country (United States), the rate of reactivation was 2.3 per
100 person years in HIV-infected individuals compared to
0.070 per 100 person years in those without HIV infection
[34]. The WHO recommends that national HIV programs
should provide TB preventive treatment for HIV-infected
individuals with LTBI, provided that active TB has been
excluded [1]. HAART significantly reduces the likelihood of
TB in populations that have been exposed to infection [35].
Treatment of LTBI with isoniazid monotherapy in
HIV-infected patients reduces the incidence of active TB
in individuals both on and off antiretroviral therapy
[15,36]. The optimum duration of isoniazid is debated
but the WHO recommends six months, which is a trade-
off between efficacy and expected completion rates [37].
In our study, patients not on HAART were offered three
months isoniazid plus rifampicin, which is equivalent to
6-12 months isoniazid in terms of efficacy and safety
[38,39]. Preventive treatment was acceptable to patients
in our study, with an uptake of 90% and adherence of
95% among those who started therapy. This is consider-
ably better than reported completion rates of 45% in
New York City [40], and 54% in LTBI treated TB con-
tacts in the same area of London [16] and suggests that
in this population, isoniazid preventive therapy fulfils the
requirements set for its implementation [41].
Isoniazid-resistant TB occurred in one patient within
two years of completing preventive treatment with iso-
niazid monotherapy. It is not known whether resistance
was present in the original latent strain, or developed
during preventive treatment, or whether the patient was
newly infected with a resistant TB strain. Concerns have
been expressed regarding the possibility that the use of
isoniazid monotherapy in preventive treatment might in-
crease the risk of isoniazid resistant strains of TB if the
disease develops subsequently. However, a systematic re-
view reported an overall relative risk of 1.45 (CI 0.85-2.47)
comparing isoniazid-resistant strains in those given pre-
ventive treatment and placebo controls [42]. The results
were the same when studies of HIV-infected and HIV-
uninfected people were considered separately. Recent data
from South Africa show that TB developing after recent
isoniazid preventive therapy has a prevalence of drug re-
sistance similar to background levels [36]. However,
in vitro experiments have suggested that isoniazid resist-
ance is more likely due to the use of the drug [43] and that
the rate of mutation in latent TB may be the same as in
active disease [44]. The latter paper recommends the use
of a two-drug regimen for preventive treatment [31,38].
Conclusions
Screening for TB in those with HIV infection and with-
out symptoms in London (UK) yielded approximately
10% with latent infection and 1% with active disease.
This yield of latent and active TB was greater than typically
found in contact tracing, which should encourage health
care workers to implement IGRA-based TB screening in
the HIV clinic. There was a high completion rate for pre-
ventive treatment in those with a positive test result, and
follow up of treated individuals will provide valuable
insights into the long-term effects of preventive treatment.
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